Viewing nowCombinationLibica Tablet 10/40 mg
Olmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.

MFDS item code 201406169 · Approved 2014.12.31 · Insurance code 663606540
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively lower and control blood pressure in patients with essential hypertension for whom blood pressure control is difficult with monotherapy of Amlodipine or Olmesartan Medoxomil. This helps reduce the risk of cardiovascular complications and improve health.
Administer 1 tablet of this drug once daily with water, regardless of meals. It is recommended, if possible, to take it at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the dose of the individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ○ Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while monitoring their condition closely. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be monitored closely. This drug should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this drug, under Precautions for Use.) ○ Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
○ Children: The safety and efficacy of this drug in pediatric patients under 18 years of age have not been established.
This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this medication's active ingredients or similar compounds, those who are pregnant or breastfeeding, those with severe liver impairment or heart valve disease, biliary obstruction patients, renal dialysis patients, shock patients, certain diabetic patients should not take this medication. Caution is needed for patients with low blood pressure due to fluid or salt depletion, as blood pressure may drop sharply during the initiation of treatment. Monitoring is necessary, as vasodilation may lead to hypotension. Patients with heart disease or heart failure should be cautious when taking this medication, and patients with impaired renal function should consult a doctor before use. This medication can cause various side effects including dizziness, headache, hypotension, edema, indigestion, rash; if any unusual symptoms occur, medical personnel should be notified immediately. This medication may interact with other medications, so if any medications are currently being taken, it is essential to inform a doctor or pharmacist. Women who are pregnant or planning to become pregnant should not take this medication, and breastfeeding women should discontinue breastfeeding or consult a doctor if they take this medication. This medication is not recommended for children under 18 years of age as its safety and efficacy have not been established. Elderly patients may have decreased kidney and liver function, requiring careful dosage adjustment and monitoring while on this medication. In case of overdose, severe hypotension and symptoms due to vasodilation may occur, so immediate medical attention should be sought. This medication should be stored out of reach of children and kept in a tightly sealed container away from moisture and direct sunlight.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture from entering, ideally at a temperature between 1 to 30 degrees Celsius at room temperature. Proper storage will help maintain the medication's efficacy and prevent degradation.
Brownish red round film-coated tablet
30 tablets/box [10 tablets/PTP X 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.